Janssen Pharmaceuticals Inc.

Latest Janssen Pharmaceuticals Inc. Items
  • Arkansas court won't reconsider Risperdal case

    The Arkansas Supreme Court declined on Thursday to reconsider its decision that threw out a $1.2 billion judgment against a pharmaceutical company accused of improperly marketing an antipsychotic drug.


  • Arkansas AG asks court to reconsider drug ruling

    Arkansas Attorney General Dustin McDaniel asked the state Supreme Court on Monday to reconsider its decision tossing out a $1.2 billion judgment against drugmaker Johnson & Johnson, saying justices did "significant harm" to the state and broke from 170 years of precedent.


  • Arkansas to ask court to reconsider drug fine

    Arkansas Attorney General Dustin McDaniel said Thursday he plans to ask the state Supreme Court to reconsider its decision tossing out a $1.2 billion judgment against drugmaker Johnson & Johnson over the marketing of the antipsychotic drug Risperdal.


  • FILE - In this file photo taken Nov. 19, 2013, Arkansas Attorney General Dustin McDaniel speaks at a Little Rock, Ark., news conference. The Arkansas Supreme Court on Thursday, March 20, 2014, overturned a $1.2 billion judgment against Johnson & Johnson in a lawsuit challenging the drugmaker's marketing of an antipsychotic drug. (AP Photo/Danny Johnston, File)

    Arkansas court tosses $1.2B judgment against J&J

    The Arkansas Supreme Court tossed out a $1.2 billion judgment against Johnson & Johnson on Thursday, reversing a lower court verdict that found the drug maker engaged in fraudulent tactics when marketing the antipsychotic drug Risperdal.


  • Drug firms argue against $1.2B Arkansas judgment

    A lawyer for two pharmaceutical companies argued Thursday that the Arkansas Supreme Court should reverse a $1.2 billion judgment because the trial judge improperly applied a law in the state's lawsuit over improper marketing of the antipsychotic drug Risperdal.


  • Oral arguments set over J&J appeal of $1B fine

    The Arkansas Supreme Court has scheduled oral arguments in Johnson & Johnson's request to overturn a verdict and $1.2 billion fine over the marketing of the antipsychotics drug Risperdal.


  • Arkansas judge fines J&J $1.1B in Risperdal case

    An Arkansas judge has fined Johnson & Johnson and a subsidiary more than $1.1 billion after a jury found the companies downplayed and hid risks associated with an antipsychotic drug.


  • Arkansas judge to decide penalty in J&J trial

    A judge will decide how much a Johnson & Johnson and a subsidiary must pay the state of Arkansas, after a jury found the company downplayed and hid risks associated with an antipsychotic drug.


  • Johnson & Johnson settles Texas lawsuit for $158M

    Texas and a subsidiary of health care giant Johnson & Johnson reached a $158 million settlement in a Medicaid fraud lawsuit Thursday, allowing the drugmaker to pay a fraction of the potential $1 billion in penalties and fines that state officials had initially sought.


Happening Now